TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: chest tube drainage duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete Re-epithelization of all lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety and tolerability of S-equol
Endpoint domain: Adverse events/effects
Primary endpoint: Hope (Herth Hope Index)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Life (MacGill Quality of Life Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knowledge assessment in IVF patients
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence and incidence of bilateral Ménière's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Variation of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of manifestations related to clinical worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial innocuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: knee biomechanics during single leg hop landing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: condylar volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of mandibular advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of chest/abdominal wall varices and spider nevi on survival
Endpoint domain: Mortality/survival
Primary endpoint: Pathophysiology of gliomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of diabetes and pre-diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluation of the Strength of Core Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evaluation of the Endurance of Core Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Behavioural intention to prescribe antibiotics
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Behavioural simulation (prescribing behaviour)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Peak of Circulating Tumor Cells (CTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: early postoperative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: leak
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lower Back Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in malodor of axillary osmidorsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Mental Health Related Quality of Life/Functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Time to Stand (TTSTAND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NO production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PGE2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose Normalized Area Under the Concentration-Time Curve (AUCtau,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Normalized Maximum Steady-state Concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Normalized Average Steady-state Drug Concentration (Css,Av)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of NoL Index with noxious stimulation/analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With Grade 3/4 Clinical Congestive Heart Failure (CHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity and specificity of the Mini Nutritional Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Socket Soft Tissue Gap Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective cognitive complaint
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immediate and Long Term Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombogenic mechanisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of respiratory rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Bupivicaine in Milligrams Administered Per Hour of Labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Retrieved Lymph Nodes Per Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the Relative Abundance of Lactobacillus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Wheelchair Skills Test (WST)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: C12 EFV concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic complete response (pCR)
Endpoint domain: Mortality/survival
Primary endpoint: time to first psychiatric relapse
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients Operated Via da Vinci Robot
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Eotaxin-3 and IL-27 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of SSRI/SNRI antidepressant drugs in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Assessment Tool Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of faecal dry weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MRD negativity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of absorption of aripiprazole OSF 10mg versus Abilify ® 10mg tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Assessment of Quality-of-Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MIB Positive (Percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Percentage of Misuse for Non-Therapeutic Reasons
Endpoint domain: Adverse events/effects
Primary endpoint: Error rate in facial emotion judgements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in trough seated DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tumor response rate based on change in tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean difference change in proliferative index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: immune cell infiltration and immune checkpoint expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitative analysis of vitamin D, B9, B12 and lutein in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantitative analysis of vitamin B9 and B12 in the liquid fraction of food boluses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory cytokines profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of Non-HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: OMERACT-OARSI response criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Application of in vitro maturation (IVM) of oocytes as a laboratory tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Appreciation of IVM as a laboratory technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Laboratory confirmed upper respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicities (DLT) of FF-10850
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of FF-10850
Endpoint domain: Adverse events/effects
Primary endpoint: Retention rate at week 16
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in obsessive beliefs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Vascular Occlusive Events (VOEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rates of Nausea or Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of routine clinical assessment abnormalities reported as adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of safety laboratory assessment abnormalities reported as adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with study related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: PK parameters (concentration, exposure, half-life) of VX-809
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters (concentration, exposure, half-life) of VX-770
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCL-90-R questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short form of the Inventory of Interpersonal Problems (IIP-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative proportion of patients with severe chemotherapy induced thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SARC-F
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FRAIL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Duration of feeding and/or drinking difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation and connectivity of frontal cortex and limbic region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of scores on Apathy Evaluation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Sexual Functioning Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time of safe apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Drug adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete wound closure of skin graft donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in peripheral blood CD117+ cells per ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive status assessed by 3M score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in weight self-stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in eating behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in obesity-related quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: delayed days of birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allograft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety disorders and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Non-scheduled hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: True Cleft Area in mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2nd or 3rd degree heart block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with Richmond Agitation-Sedation score =0, -1, -2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in stroke volume and impedance variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective health and well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean change from baseline in best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically relevant changes in 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean total number of migraine/migrainous headache days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in prostate-specific antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Subject safety measured by serial ECGs
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs measured on Days 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and frequency of subjects who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 11-point numerical rating scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alcohol and Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of chronic headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood gas analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrement of oVEMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving therapeutic cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of rescue narcotics consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol and fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the percentage of subjects that return to baseline facial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lost to follow-up rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in healthy lifestyle behaviours
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in memory strategy use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attainment of individualized goals for lifestyle change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of Responder according to IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants achieving complete renal remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Success in induction of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Blood Lactate Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in Laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral retinal ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Absolute C-reactive Protein (CRP) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Smoking Lapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants That Become Infected (Individual Strains)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Participants That Become Infected (Mixed Inocula)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dry mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive Range of Motion Recovery of the Shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants choosing treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: time to maximal glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success in PICC placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Attention Deficit / Hyperactivity Disorder Total Sum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total units of allogeneic blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Impaired renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume of Allogenic Blood Transfused Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in hemoglobin HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: platelet aggregation in response to arachidonic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum levels of Apelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of Chemerin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of All-cause Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of adverse medical events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serious respiratory morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Follow-up of neurological development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Result from Ishihara Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who achieved target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of patients who achieved target LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacodynamic aspects of muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of patients with full recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients having complication
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analogue scale (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee range of movement (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps and hamstrings muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes